Cadila Healthcare is currently trading at Rs. 464.10, up by 1.90 points or 0.41% from its previous closing of Rs. 462.20 on the BSE.

The scrip opened at Rs. 455.00 and has touched a high and low of Rs. 466.50 and Rs. 452.25 respectively. So far 73406 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 509.35 on 15-Jan-2021 and a 52 week low of Rs. 212.70 on 13-Mar-2020.

Last one week high and low of the scrip stood at Rs. 473.20 and Rs. 452.25 respectively. The current market cap of the company is Rs. 47491.42 crore.

The promoters holding in the company stood at 74.88%, while Institutions and Non-Institutions held 17.15% and 7.97% respectively.

Zydus Cadila has been granted ‘Orphan Drug Designation’ (ODD) by United States Food and Drug Administration (USFDA) to Saroglitazar Mg for the treatment of patients with Primary Biliary Cholangitis (PBC). Orphan drug designation provides eligibility for certain development incentives, including tax credits for qualified clinical testing, prescription drug user fee exemptions and seven-year marketing exclusivity upon FDA approval. This follows the grant of ‘Fast Track Designation’ by the USFDA to Saroglitazar Mg for PBC in December 2020.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Zydus Lifesciences Share Price

931.45 -3.75 (-0.40%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×